Drug Profile


Alternative Names: OMS-201

Latest Information Update: 02 Oct 2015

Price : $50

At a glance

  • Originator Omeros Corporation
  • Class Antispasmodics; Dihydropyridines; Muscle relaxants; Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules
  • Mechanism of Action Calcium channel antagonists; Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Suspended Inflammation; Pain; Spasm

Most Recent Events

  • 04 May 2012 Omeros plans a phase II programme for Inflammation, Pain and Spasm
  • 30 Dec 2010 Final adverse events data from a Phase-I/II trial in Inflammation, Pain and Spasm released by Omeros
  • 30 Dec 2010 Omeros completes Phase-I/II clinical trials in surgically induced Inflammation, Pain and Spasm in USA (Transurethral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top